Definium Therapeutics Raises $700M in Upsized Public Offering — Definium Therapeutics, Inc.

Event summary

Definium Therapeutics priced a $700M upsized public offering of 20.6M common shares at $34.00 per share.
The company granted underwriters a 30-day option to purchase an additional 3.1M shares.
Proceeds will fund R&D, commercialization prep for DT120 ODT, and general corporate purposes.
The offering is expected to close on June 25, 2026, subject to customary closing conditions.

The big picture

Definium's $700M raise underscores the growing investor appetite for late-stage biopharmaceutical companies targeting psychiatric disorders. The upsizing of the offering signals strong demand, but the company will need to demonstrate tangible progress in its clinical pipeline to justify the valuation. This funding round positions Definium as a key player in the psychedelics-for-therapeutics space, competing with both traditional pharma and emerging biotechs.

What we're watching

Clinical Progress: How the pace of DT120 ODT's clinical development will impact investor confidence and valuation.
Market Positioning: Whether Definium can sustain its lead in applying scientific rigor to psychedelics for psychiatric disorders.
Proceeds Utilization: The efficiency with which Definium allocates the $700M towards R&D and commercialization efforts.